Novartis, BIO Suggest Expanding Hematologic Disorder Guidance

Novartis and BIO sent feedback to the FDA about its draft guidance on developing treatments for severely debilitating or life-threatening (SDLT) hematologic disorders, urging the agency to broaden its guidance.
Source: Drug Industry Daily